Alkermes obtains orphan drug designations for alixorexton in US and EU

Alkermes announced that its investigational narcolepsy and idiopathic hypersomnia treatment alixorexton received orphan drug designations from the FDA and European Commission, providing development incentives and market exclusivity if approved. The designations support the company's ongoing phase 3 Brilliance Studies and phase 2 Vibrance-3 study, potentially establishing a differentiated treatment option for rare sleep disorders.